Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP26A1 | O43174 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | CYP26B1 | Q9NR63 | 2/20 | 0.45 |
| ▸ | RARB | P10826 | 6/20 | 0.43 |
| ▸ | RARG | P13631 | 6/20 | 0.43 |
| ▸ | RARA | P10276 | 5/20 | 0.43 |
| ▸ | CRABP2 | P29373 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 11/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | HNF4A | P41235 | 4/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3065406 | 0.91 | RARA (0.41) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3073954 | 0.91 | CYP26A1 (0.46) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3062965 | 0.91 | RXRA (0.37) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3070732 | 0.91 | RXRA (0.37) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3072959 | 0.91 | RARG (0.41) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3065794 | 0.90 | RXRA (0.36) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3067253 | 0.90 | RXRA (0.36) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3063388 | 0.90 | CYP26A1 (0.43) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3053310 | 0.89 | CYP26A1 (0.45) | CYP26A1CYP3A4CYP26B1RARBRARG | |
| SCHEMBL3072932 | 0.89 | RXRA (0.37) | CYP26A1CYP3A4CYP26B1RARBRARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160310439-A1 | LIPID MICROCAPSULES PREFERABLY COMPRISING A RETINOID, AND COMPOSITION CONTAINING SAME, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME IN DERMATOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-10-27 | — | — | US | claimed |
| US-20150190372-A1 | MICROCAPSULES CONTAINING RETINOIDS, METHOD OF PREPARING SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-07-09 | — | — | US | claimed |
| US-20150125520-A1 | LIPID NANOCAPSULES COMPRISING A RETINOID, NANODISPERSION AND COMPOSITION CONTAINING THE SAME, PROCESS FOR PREPARING THE SAME AND USE THEREOF IN DERMATOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2015-05-07 | — | — | US | claimed |
| US-20120282314-A1 | DERMATOLOGICAL/COSMETIC SKIN DEPIGMENTING COMPOSITIONS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-11-08 | — | — | US | claimed |
| US-7767650-B2 | Ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-08-03 | — | — | US | claimed |
| US-20100143445-A1 | Dermatological/cosmetic skin depigmenting compositions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | claimed |
| EP-1694627-B1 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2009-05-27 | — | — | EP | claimed |
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-24 | — | — | US | claimed |
| EP-1694627-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | claimed |
| WO-2005056510-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | claimed |
| CN-113559083-A | Lipid microcapsules comprising a retinoid | 盖尔德马研究及发展公司 | 2021-10-29 | — | — | CN | disclosed |
| US-10925822-B2 | Process for preparing a dermatological composition comprising oleosomes | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2021-02-23 | — | — | US | disclosed |
| US-10772807-B2 | Lipid microcapsules preferably comprising a retinoid, and composition containing same, method for the production thereof, and use of same in dermatology | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-09-15 | — | — | US | disclosed |
| US-10702604-B2 | Lipid nanocapsules comprising a retinoid, nanodispersion and composition containing the same, process for preparing the same and use thereof in dermatology | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2020-07-07 | — | — | US | disclosed |
| US-20160310439-A1 | LIPID MICROCAPSULES PREFERABLY COMPRISING A RETINOID, AND COMPOSITION CONTAINING SAME, METHOD FOR THE PRODUCTION THEREOF, AND USE OF SAME IN DERMATOLOGY | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2016-10-27 | — | — | US | disclosed |
| US-20100143445-A1 | Dermatological/cosmetic skin depigmenting compositions | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2010-06-10 | — | — | US | disclosed |
| EP-1694627-B1 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RES & DEV (FR) | 2009-05-27 | — | — | EP | disclosed |
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-05-24 | — | — | US | disclosed |
| EP-1694627-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | Galderma Research & Development, S.N.C. (FR) | 2006-08-30 | — | — | EP | disclosed |
| WO-2005056510-A2 | NOVEL LIGANDS THAT ARE ACTIVATORS OF THE RAR RECEPTORS, USE IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT, S.N.C. (FR) | 2005-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070117761-A1 | Novel ligand activators of the RAR receptors and pharmaceutical/cosmetic applications thereof | RARA, RARB, RARG | CYP26A1 191/4885CYP3A4 1550/4885CYP26B1 367/4885 |
| US-10925822-B2 | Process for preparing a dermatological composition comprising oleosomes | LIPA, CUTA, RAB5IF | CYP26A1 3455/4885CYP3A4 4747/4885CYP26B1 2815/4885 |
| US-20120282314-A1 | DERMATOLOGICAL/COSMETIC SKIN DEPIGMENTING COMPOSITIONS | TYR, RARA, MITF | CYP26A1 1558/4885CYP3A4 4682/4885CYP26B1 1431/4885 |
| US-20100143445-A1 | Dermatological/cosmetic skin depigmenting compositions | TYR, RARA, MITF | CYP26A1 1558/4885CYP3A4 4682/4885CYP26B1 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.